Gastric emptying and related symptoms in patients treated with buspirone, amitriptyline or clebopride: a "real world" study by 13C-octanoic Acid Breath Test(40 visite) Caviglia GP, Sguazzini C, Cisaro F, Ribaldone DG, Rosso C, Fagoonee S, Smedile A, Saracco GM, Astegiano M, Pellicano R
MINERVA MED (ISSN: 0026-4806), 2017 Dec; 108(6): 489-495.
Tipo di articolo: Journal Article,
Impact factor: 2.863, Impact factor a 5 anni: 1.515
Url: Non disponibile.
Parole chiave: Adult, Amitriptyline, Pharmacology, Therapeutic Use, Benzamides, Breath Tests, Buspirone, Caprylates, Analysis, Domperidone, Drug Evaluation, Drug Resistance, Dyspepsia, Drug Therapy, Metabolism, Physiopathology, Female, Gastric Emptying, Drug Effects, Humans, Middle Aged, Postprandial Period, Proton Pump Inhibitors, Retrospective Studies, Satiation,
*** IBB - CNR *** Department of Medical Sciences, University of Turin, Turin, Italy - firstname.lastname@example.org., Unit of Gastroenterology and Hepatology, Citta della Salute e della Scienza, Molinette Hospital, Turin, Italy., Department of Medical Sciences, University of Turin, Turin, Italy., Institute for Biostructures and Bioimages CNR c/o Molecular Biotechnology Center, University of Turin, Turin, Italy.,
BACKGROUND: Gastric motility is a key-factor in the pathogenesis of functional dyspepsia (FD). 13C-octanoic Acid Breath Test (OBT) is a tool used for measuring gastric emptying time in clinical setting. We aimed to investigate the variation in FD symptoms and OBT parameters after treatment with buspirone, amitriptyline or clebopride. METHODS: Between Jan-2007 and Dec-2014, we enrolled 59 patients with FD unresponsive to first-line therapy with proton pump inhibitors and/or domperidone that underwent OBT before and after 3 months of buspirone (N.=32), amitriptyline (N.=16) or clebopride (N.=11) treatment. RESULTS: Early satiation severity was positively correlated with gastric half emptying time (t1/2) (r=0.3789, P=0.003) and gastric lag phase (r=0.3371, P=0.011), and negatively correlated with gastric emptying coefficient (r=-0.3231, P=0.015). A reduction in t1/2 measurement in association to postprandial fullness, and early satiation severity improvement was observed (P=0.009, P=0.005 and P<0.001, respectively). Patients treated with buspirone obtained both a decrease in t1/2 (P=0.005) and an amelioration in early satiation (P=0.001). Patients under amitriptyline treatment experienced an improvement in postprandial fullness (P=0.046), whereas no variation was reported in patients treated with clebopride. CONCLUSIONS: Patients with FD, non-responders to first-line therapy and reporting meal-related discomfort, may benefit from buspirone or amitriptyline-based therapies.
Kim YH, Shin SW, Pellicano R, Fagoonee S, Choi IJ, Kim YI, Park B, Choi JM, Kim SG, Choi J, Park JY, Oh S, Yang HJ, Lim JH, Im JP, Kim JS, Jung HC, Ponzetto A, Figura N, Malfertheiner P, Choi IJ, Kook MC, Kim YI, Cho SJ, Lee JY, Kim CG, Park B, Nam BH, Bae SE, Choi KD, Choe J, Kim SO, Na HK, Choi JY, Ahn JY, Jung KW, Lee J, Kim DH, Chang HS, Song HJ, Lee GH, Jung HY, Seta T, Takahashi Y, Noguchi Y, Shikata S, Sakai T, Sakai K, Yamashita Y, Nakayama T, Leja M, Park JY, Murillo R, Liepniece-karele I, Isajevs S, Kikuste I, Rudzite D, Krike P, Parshutin S, Polaka I, Kirsners A, Santare D, Folkmanis V, Daugule I, Plummer M, Herrero R, Tsukamoto T, Nakagawa M, Kiriyama Y, Toyoda T, Cao X, Corral JE, Mera R, Dye CW, Morgan DR, Lee YC, Lin JT, Garcia Martin R, Matia Cubillo A, Lee SH, Park JM, Han YM, Ko WJ, Hahm KB, Leontiadis GI, Ford AC, Ichinose M, Sugano K, Jeong M, Park JM, Han YM, Park KY, Lee DH, Yoo JH, Cho JY, Hahm KB, Bang CS, Baik GH, Shin IS, Kim JB, Suk KT, Yoon JH, Kim YS, Kim DJ * Helicobacter pylori Eradication for Prevention of Metachronous Recurrence after Endoscopic Resection of Early Gastric Cancer(20 visite) NEW ENGL J MED (ISSN: 0028-4793), 2015 Jun; 30642104201566393291: 749-756. Impact Factor:59.558 DettagliEsporta in BibTeXEsporta in EndNote
147 Records (135 escludendo Abstract e Conferenze). Impact factor totale: 627.27 (576.798 escludendo Abstract e Conferenze). Impact factor a 5 anni totale: 659.539 (602.176 escludendo Abstract e Conferenze).